|
TIMEPOINT
|
Baseline
|
Allocation
|
Follow-up
|
|---|
| |
Mo. 0
|
Mo. 12
|
Mo. 24
|
Mo. 36
|
|---|
|
ENROLMENT:
|
|
Community eligibility screen
|
X
| | | | |
|
Informed consent
|
X
| | | | |
|
Census
|
X
| |
X
|
X
|
X
|
|
Allocation
| |
X
| | | |
|
INTERVENTIONS:
|
|
Annual Azithromycin MDA
| |
X
|
X
|
X
|
(X)a
|
|
No treatment
| |
X
|
X
|
X
|
(X)a
|
|
ASSESSMENTS:
|
|
Conjunctival swabs
|
X
| | | |
X
|
|
Conjunctival photography
|
X
| | | |
X
|
|
Dried blood spot collection
|
X
| | | |
X
|
- aCommunities will receive mass drug administration with azithromycin per Niger trachoma program guidelines at and after the 36-month study visit, depending on the prevalence of trachomatous inflammation--follicular
